Table 4.

Results of univariate and multivariate Cox regression models for time to local progression.

Factor	Hazard ratio (95% confidence interval)	p-value
Univariate
Age	1.001 (0.946, 1.060)	0.962
CA19-9 at diagnosis	0.99997 (0.99974, 1.00019)	0.769
Pre-SBRT CA19-9	0.9996 (0.9986, 1.0005)	0.359
Post-SBRT CA19-9	1.00038 (1.00006, 1.00071)	0.022
Change in CA19-9	1.0003 (0.9998, 1.0008)	0.196
CA19-9 normalization	1.01 (0.28, 3.61)	0.9912
Previous EBRT Dose	0.01 (0.00, infinity)	1.000
Recurrent lesion vs. non-recurrent	3.31 (1.42, 7.68)	0.005
GTV volume	1.005 (0.988, 1.021)	0.570
PTV volume	1.01 (0.98, 1.03)	0.543
BED ≥ 60	2.09 (0.50, 8.73)	0.3136
Multiple fractions vs. single fraction	0.45 (0.23, 0.88)	0.019
Chemo: Gemcitibine + Capcitabine vs. Gemcitibine	0.51 (0.21, 1.24)	0.138
Chemo: FU based vs. Gemcitibine	0.62 (0.14, 2.72)	0.528
Stage	0.87 (0.59, 1.28)	0.45
Surgery vs. no surgery	0.83 (0.41, 1.69)	0.615
Dose	0.94 (0.89, 1.00)	0.049
Multivariate
Recurrent lesion	5.10 (1.56, 16.64)	0.007
Post-SBRT CA19-9	1.0005 (1.0001, 1.0008)	0.011